Grifols SA

GRFS

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    23,800

Grifols SA News & Analysis

stocks

6 undervalued stocks with low beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,154.9026.00-0.28%
CAC 408,222.7939.37-0.48%
DAX 4024,339.50263.54-1.07%
Dow JONES (US)49,501.30260.310.53%
FTSE 10010,333.5968.75-0.66%
HKSE26,885.2437.920.14%
NASDAQ22,904.58350.61-1.51%
Nikkei 22553,818.04475.32-0.88%
NZX 50 Index13,444.0223.27-0.17%
S&P 5006,882.720.000.00%
S&P/ASX 2008,889.2014.80-0.17%
SSE Composite Index4,075.9226.29-0.64%

Market Movers